|
[Related PubMed/MEDLINE]
Total Number of Papers: 55
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: IXE |
| Long Form |
: ixekizumab |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons. |
ADA, ASAS, ASDAS, BASFI, bDMARDs, CRP, CZP, ETN, ITC, MRI, OSI, SEC, SLR |
| 2 |
2023 |
Economic Evaluation of Selected Interleukin Inhibitors Versus Methotrexate for Moderate-to-Severe Plaque Psoriasis, From the Philippine Payer Perspective. |
GoP, ICERs, ILIs, MTX, PHP, SEC |
| 3 |
2023 |
Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. |
IR, PY, TEAEs |
| 4 |
2023 |
Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience. |
AEs, DMARDs, HR, PsA |
| 5 |
2022 |
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52Weeks: Data from Three PhaseIII Randomised Controlled Trials. |
nr-axSpA, r-axSpA |
| 6 |
2022 |
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). |
CI, DLQI, FMA, IL, OR, PSoHO, sPGA |
| 7 |
2022 |
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. |
bDMARD |
| 8 |
2022 |
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months. |
ICER, PPPM, SEC |
| 9 |
2022 |
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings. |
ADA, HCRU, ICER |
| 10 |
2022 |
Ixekizumab four-week dosing is comparable to two-week dosing in psoriasis patients and reduces treatment costs: experience in a real-world setting over a 12-week period |
DLQI, PASI |
| 11 |
2022 |
Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study. |
ADA, IPTW |
| 12 |
2022 |
Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases. |
ADA, ETN, IPTW, SEC, UST |
| 13 |
2022 |
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study. |
ASDAS, OL, RWRP |
| 14 |
2022 |
The effect of therapy on TRM in psoriatic lesions. |
ADA, MTX, SEC, TRM |
| 15 |
2021 |
Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. |
axSpA, SEC |
| 16 |
2021 |
Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature. |
AEs, DLQI, IL-17A, PASI, PGA, SEC |
| 17 |
2021 |
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18Months. |
PDC, SEC |
| 18 |
2021 |
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). |
ASDAS, axSpA, COAST-Y, PBO, RWRP |
| 19 |
2021 |
Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population. |
ADA, CER, ETA, GUS, PDC, SEC, UST |
| 20 |
2021 |
Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study. |
DLQI, HRQoL, IL, PASI, UST |
| 21 |
2021 |
Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors. |
DAPSA, DAS28-CRP, EULAR, HAQ-DI, MDA, PBO, TNFi |
| 22 |
2021 |
Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis. |
EU, US |
| 23 |
2021 |
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. |
ACR, MTX, PsA |
| 24 |
2021 |
Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice. |
ADA, SEC |
| 25 |
2021 |
Real-World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study. |
ICER, PDC, PPPM, PsA |
| 26 |
2021 |
Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. |
mSASSS, r-axSpA |
| 27 |
2021 |
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2). |
DLQI, NAPSI, PPASI, PSSI |
| 28 |
2021 |
T cell functions of psoriatic arthritis patients are regulated differently by TNF, IL-17A and IL-6 receptor blockades in vitro. |
ADA, IL-17A, IL-6R, PBMCs, PHA, TCZ, TNF-alpha |
| 29 |
2021 |
Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. |
ADA, CER, ETA, GUS, PsA, PsO, SEC, UST |
| 30 |
2020 |
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). |
sPGA 0,1 |
| 31 |
2020 |
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naive Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. |
ADA, csDMARDs, MTX, PsA |
| 32 |
2020 |
Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis. |
AS, bDMARDs, BKZ, SEC, TNFi |
| 33 |
2020 |
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). |
NAPSI, PASI, UST |
| 34 |
2020 |
Ixekizumab for the treatment of ankylosing spondylitis. |
AS |
| 35 |
2020 |
Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. |
ADA, bDMARD, EQ-5D-5L, PBO, r-axSpA, TNFi |
| 36 |
2020 |
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. |
--- |
| 37 |
2020 |
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. |
ACR, ADA, csDMARD, PASI, PsA, Wk |
| 38 |
2020 |
Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis. |
HAQ-DI, NRS, PROs, PsA, VAS |
| 39 |
2020 |
Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports. |
PsA |
| 40 |
2019 |
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. |
ADA, csDMARDs, PsA |
| 41 |
2019 |
Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab. |
ADA, ICER, IPTW, PMPM, PsO, SEC |
| 42 |
2019 |
Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. |
ADA, DLQI, FAE, INF, MID, MTX, PASI, SEC |
| 43 |
2019 |
Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. |
AUC, DLQI, Itch NRS, PASI, UST |
| 44 |
2019 |
Ixekizumab for treating ankylosing spondylitis. |
axSpA, IL-17i, TNFi |
| 45 |
2019 |
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. |
MI, mNRI |
| 46 |
2018 |
A review of ixekizumab in the treatment of psoriatic arthritis. |
csDMARDs, IgG4, PsA, TNFi |
| 47 |
2018 |
Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis. |
Itch NRS, PASI, PatGA, sPGA |
| 48 |
2018 |
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. |
ETN, NRS, PASI, PBO |
| 49 |
2018 |
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. |
PASI |
| 50 |
2017 |
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. |
DLQI, IL, NRS, sPGA, UST |
| 51 |
2017 |
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. |
PBO, sPGA |
| 52 |
2017 |
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). |
ACR, ADA, EPP, PBO, PsA |
| 53 |
2017 |
Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. |
ETN, HRQoL, PASI |
| 54 |
2017 |
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials. |
DLQI, ETN, PRD |
| 55 |
2017 |
Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants. |
CI, IL |
|
A Search Service for Abbreviation / Long Form
